Prospective study to assess with Continuous Glucose Monitoring (CGM) the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in Type 2 Diabetes (T2DM) patients with renal impairment - Renal-TIR

Start Date09 May 2022

Sponsor / Collaborator-

ChiCTR2000040250 / SuspendedEarly Phase 1IIT

Observation on the efficacy of application in the treatment of type 2 diabetes with insulin glargine

Start Date01 Mar 2021

Sponsor / Collaborator-

ChiCTR-IIR-17011018 / SuspendedPhase 4IIT

Study of efficacy and safety of higher starting dose of insulin glargine in overweight and obese newly-diagnosed hospitalized patients with type 2 diabetes

Start Date30 May 2017

Sponsor / Collaborator

Shenzhen Second People's Hospital

100 Clinical Results associated with Insulin Glargine(Samsung Bioepis Co., Ltd.)

100 Translational Medicine associated with Insulin Glargine(Samsung Bioepis Co., Ltd.)

100 Patents (Medical) associated with Insulin Glargine(Samsung Bioepis Co., Ltd.)

2,121

Literatures (Medical) associated with Insulin Glargine(Samsung Bioepis Co., Ltd.)

01 Feb 2024·Hospital pharmacy

Insulin Glargine Associated Nausea in a Patient Seen by a Collaborative Drug Therapy Management Pharmacist in an Urban Community Hospital: A Case Report

Author: Gerber, Anthony ; Quinn, Rachel

Background: Diabetes mellitus has become increasingly prevalent and a considerable health risk in the United States. Early introduction of insulin can improve overall health outcomes of patients with diabetes. With the development of long-acting insulin analogs, such as insulin glargine, limitations such as variable absorption and hypoglycemia were reduced. Majority of reported adverse drug effects secondary to insulin glargine include injection site reaction and hypoglycemia. There is limited data on gastrointestinal adverse effects, including nausea, of insulin glargine. Case Presentation: A 51-year-old female with a past medical history of type 2 diabetes was referred to the collaborative drug therapy management pharmacist for diabetes education and management. The patient was initiated on insulin glargine (Lantus®) and began to experience episodes of nausea and emesis over a 9 week period. Once the patient was switched from insulin glargine (Lantus®) to insulin detemir, symptoms subsided. Upon re-trial of insulin glargine (Lantus®), nausea and emesis-like symptoms resumed. A probable relationship between insulin glargine (Lantus®) and the reaction was estimated using the Naranjo Adverse Drug Reaction Probability Scale. Conclusion: Potential mechanisms behind the relationship of insulin glargine (Lantus®) and nausea are hypothesized, however there is limited literature supporting this claim and further investigation is warranted.

01 Feb 2024·Diabetes, obesity & metabolism

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

Article

Author: Bolli, Geremia B ; Frier, Brian M ; Landgraf, Wolfgang ; Owens, David R

Abstract:

Introduction:

To compare responses to basal insulin glargine 300 U/ml (IGlar‐300) and 100 U/ml (IGlar‐100) in newly defined subphenotypes of type 2 diabetes.

Methods:

Insulin‐naive participants (n = 858) from the EDITION 3 trial were assigned to subphenotypes ‘Mild Age‐Related Diabetes (MARD)’, ‘Mild Obesity Diabetes (MOD)’, ‘Severe Insulin Resistant Diabetes (SIRD)’ and ‘Severe Insulin Deficient Diabetes (SIDD)’. Key variables were analysed at baseline and 26 weeks.

Results:

Participants were comprised of MOD 56.1% (n = 481), SIDD 22.1% (n = 190), MARD 18.2% (n = 156) and SIRD 3.0% (n = 26). After 26 weeks a similar decrease in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) of 16‐19 mmol/mol and 1.4‐1.7 mmol/L, respectively, occurred in MARD and MOD with both insulins. SIDD had the most elevated HbA1c and FPG (80‐83 mmol/mol/11.1‐11.4 mmol/L) and reduction in both HbA1c and FPG was greater with IGlar‐100 than with IGlar‐300 (−18 vs. −15 mmol/mol and −1.6 vs. −1.3 mmol/L, respectively; each p = .03). In SIDD, despite receiving the highest basal insulin doses, HbA1c decline (57‐60 mmol/mol/7.3‐7.6%) was suboptimal at week 26. In MOD and SIDD lower incidences with IGlar‐300 were found for level 1 nocturnal hypoglycaemia [odds ratio (OR) 0.59, 95% confidence intervals (CI) 0.36‐0.97; OR 0.49, 95% CI 0.24‐0.99]. In addition, fewer level 2 hypoglycaemia episodes occurred at any time with IGlar‐300 in SIDD (OR 0.31, 95% CI 0.13‐0.77).

Conclusion:

Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add‐on treatment to basal insulin is required to achieve glycaemic targets.

01 Feb 2024·Diabetes, obesity & metabolism

5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine

Article

Author: Ali, Mohammed K ; Laiteerapong, Neda ; Shao, Hui ; Niu, Shu ; Alkhuzam, Khalid A ; Guo, Jingchuan ; Schatz, Desmond A ; Shi, Lizheng ; Fonseca, Vivian ; Guan, Dawei ; Jiao, Tianze

Abstract:

Aim:

This study compared the 5‐year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model.

Research Design and Methods:

This study was a 5‐year SURPASS‐2 trial extrapolation, with an insulin glargine arm added as an additional comparator. The 1‐year treatment effects of tirzepatide (5, 10 or 15 mg), semaglutide (1 mg) and insulin glargine on glycated haemoglobin, systolic blood pressure, low‐density lipoprotein and body weights were obtained from the SUSTAIN‐4 and SURPASS‐2 trials. We used the BRAVO model to predict 5‐year complications for each study arm under two scenarios: the 1‐year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).

Results:

When compared with insulin glargine, we projected a 5‐year risk reduction in cardiovascular adverse events [rate ratio (RR) 0.64, 95% confidence interval (CI) 0.61‐0.67] and microvascular composite (RR 0.67, 95% CI 0.64‐0.70) with 15 mg tirzepatide, and 5‐year risk reduction in cardiovascular adverse events (RR 0.75, 95% CI 0.72‐0.79) and microvascular composite (RR 0.79, 95% CI 0.76‐0.82) with semaglutide (1 mg) under an optimistic scenario. Lower doses of tirzepatide also had similar, albeit smaller benefits. Treatment effects for tirzepatide and semaglutide were smaller but still significantly higher than insulin glargine under a conservative scenario. The 5‐year risk reduction in diabetes‐related complication events and mortality for the 15 mg tirzepatide compared with insulin glargine ranged from 49% to 10% under an optimistic scenario, which was reduced by 17%‐33% when a conservative scenario was assumed.

Conclusion:

With the use of the BRAVO diabetes model, tirzepatide and semaglutide exhibited potential to reduce the risk of macrovascular and microvascular complications among individuals with type 2 diabetes, compared with insulin glargine in a 5‐year window. Based on the current modelling assumptions, tirzepatide (15 mg) may potentially outperform semaglutide (1 mg). While the BRAVO model offered insights, the long‐term cardiovascular benefit of tirzepatide should be further validated in a prospective clinical trial.

News (Medical) associated with Insulin Glargine(Samsung Bioepis Co., Ltd.)

16 May 2024

·www.prnewswire.com

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists INDIANAPOLIS, May 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections. In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally. "The results of QWINT-2 and QWINT-4 are a significant milestone for the diabetes community and demonstrate that efsitora as a weekly insulin provides blood sugar control equivalent to daily basal insulins," said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly. "With efsitora, we have an opportunity to provide an innovative once-weekly solution that safely achieves and maintains A1C control, reduces treatment burden of traditional daily injections and potentially improves adherence for people with diabetes." QWINT-2 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 52 weeks. The trial randomized insulin-naïve adults with type 2 diabetes to receive efsitora once weekly or insulin degludec once daily and was also designed to assess efficacy in patients using and not using GLP-1 receptor agonists. The trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 52. For the efficacy estimand1,2, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of 6.87% and 6.95% respectively3. In a key secondary endpoint, efsitora was non-inferior to insulin degludec in A1C change among participants using and not using GLP-1 receptor agonists. Further, participants taking efsitora spent 45 minutes more time in range4 and 37 minutes more in tight range5 without additional time in hypoglycemia (blood glucose <54 mg/dL) in comparison to insulin degludec. QWINT-4 evaluated the efficacy and safety of efsitora compared to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized participants to receive efsitora once weekly or insulin glargine once daily, both of which were administered with insulin lispro. The trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 26. For the efficacy estimand, both efsitora and insulin glargine reduced A1C by 1.07% resulting in an A1C of 7.12% and 7.11%, respectively6,7. In both QWINT-2 and QWINT-4, efsitora was safe and well-tolerated with estimated combined rates of severe or clinically significant (blood glucose <54 mg/dL) hypoglycemic events per patient-year of exposure of 0.58 with efsitora vs. 0.45 with insulin degludec (QWINT-2) and 6.6 with efsitora vs. 5.9 with insulin glargine (QWINT-4). Detailed results from QWINT-2 will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024. Topline readouts from QWINT-1, QWINT-3 and QWINT-5 are anticipated later this year. About the QWINT clinical trial program The QWINT phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 4,000 people living with type 1 or type 2 diabetes across five global registration studies. QWINT-2 (NCT05362058) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 928 participants across the U.S., Brazil, Canada, China, Czechia (Czech Republic), Germany, Greece, Japan, Korea, Mexico and Puerto Rico to receive efsitora once weekly or insulin degludec once daily administered subcutaneously. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to insulin degludec. The trial was also designed to assess efficacy and safety for patients using and not using GLP-1 receptor agonists. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfa Insulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase 3 development for adults with type 1 and 2 diabetes. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. 1 The efficacy estimand represents the treatment effect had all participants adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. 2 95% CI for treatment difference (-0.22% to 0.061%). 3 From a baseline A1C of 8.21% for efsitora and 8.23% for insulin degludec. 4 Blood glucose 70-180 mg/dL. 5 Blood glucose 70-140 mg/dL. 6 From a baseline A1C of 8.18% for efsitora and insulin glargine. 7 95% CI for treatment difference (-0.13% to 0.14%). SOURCE Eli Lilly and Company

Clinical ResultPhase 3

16 May 2024

·www.fiercebiotech.com

Lilly keeps on Novo's tail by reporting weekly insulin hits primary endpoint in 2 pivotal trials

New data readouts from Eli Lilly tick off two of the five upcoming efsitora R&D milestones. Eli Lilly finds itself in a familiar position: snapping at the heels of Novo Nordisk. The Indianapolis-based drugmaker kept itself in the slipstream of its regular foe Thursday with positive top-line data from a pair of phase 3 studies of its once-weekly insulin candidate. Lilly and Novo have identified once-weekly basal insulin as a way to slash the burdens on some people with diabetes. Rather than inject 365 daily doses each year, patients could administer 52 weekly shots. Novo is close to making that vision a reality for patients in the U.S., where a FDA advisory committee is set to discuss its filing for approval of Awiqli next week. Lilly is following close behind. Having revealed the top-line success of the QWINT-4 trial late last month, Lilly reported a primary endpoint hit on a second study, QWINT-2, and shared data from both trials Thursday. The studies are part of a five-trial program that is testing Lilly’s basal insulin fusion protein and is nearing completion. QWINT-2 compared Lilly’s once-weekly insulin efsitora alfa to the daily insulin degludec in almost 1,000 adults with Type 2 diabetes who were starting basal dosing for the first time. After 52 weeks, efsitora was noninferior to daily dosing, with the A1C measure of blood sugar falling 1.34% and 1.26%, respectively, in the investigational and control arms. Lilly designed the study to assess whether the use of GLP-1 receptor agonists, such as its own Mounjaro and Novo’s Ozempic, affects the efficacy of efsitora. It turns out that the once-weekly formulation was noninferior to daily dosing in the GLP-1 subgroup. Patients on efsitora spent 45 minutes more time in range and 37 minutes more in tight range without additional time in hypoglycemia in comparison to their peers on daily doses. QWINT-4 enrolled adults with Type 2 diabetes who had previously been treated with basal insulin and at least two injections per day of mealtime insulin. After 26 weeks, efsitora was noninferior to daily insulin glargine on the primary endpoint of A1C. The measure of blood sugar fell 1.07% in both cohorts. Lilly said efsitora was safe and well tolerated in both trials. The rates of severe or clinically significant low blood glucose events per patient year of exposure were numerically higher in the efsitora cohorts. In QWINT-2, the figures were 0.58 and 0.45, respectively, in the weekly and daily arms. QWINT-4 tracked rates of 6.6 in the efsitora arm and 5.9 in the control group. The readouts tick off two of the five upcoming efsitora R&D milestones. Lilly’s remaining three phase 3 trials, which are assessing efsitora in various Type 1 and Type 2 populations, have completion dates in May and July. The drugmaker plans to report top-line data from the three studies later this year.

Phase 3Clinical ResultPhase 2

16 May 2024

·firstwordpharma.com

Lilly's once-weekly insulin matches daily regimens in pivotal diabetes studies

Eli Lilly says its once-weekly insulin product efsitora alfa (LY3209590) was on par with daily basal insulins when it comes to lowering blood glucose in adults with type 2 diabetes. The results come from the pivotal QWINT-2 and QWINT-4 studies, with readouts from three other late-stage trials due out later this year.The new findings also position Lilly to go head-to-head with a similar long-acting insulin candidate in development by rival Novo Nordisk. A competitive battle is already playing out between their respective GLP-1 drugs tirzepatide and semaglutide, which are used to treat both diabetes and weight loss, with each struggling to keep pace with demand for those products amid a booming market for obesity treatments."With efsitora, we have an opportunity to provide an innovative once-weekly solution that safely achieves and maintains A1c control, reduces treatment burden of traditional daily injections and potentially improves adherence for people with diabetes," said Jeff Emmick, Lilly's head of product development, in a statement Thursday.In QWINT-2, 928 insulin-naïve adults with type 2 diabetes were randomised to receive efsitora as a once-weekly basal insulin or Novo Nordisk's Tresiba (insulin degludec) once a day for 52 weeks. QWINT-4 included 730 adults with type 2 diabetes previously treated with basal insulin and at least two daily injections of mealtime insulin. Participants here were randomised to weekly efsitora or insulin glargine for 26 weeks, both administered with insulin lispro.Both trials met their respective primary endpoints of non-inferiority in reducing A1c versus the control group. In QWINT-2, efsitora lowered A1c by 1.34%, resulting in a final A1c level of 6.87%, while Tresiba reduced A1c by 1.26%, leading to an A1c of 6.95%.On a key secondary measure, efsitora was non-inferior to Tresiba at reducing A1c among both users and non-users of GLP-1 agonists. Moreover, compared to Novo's treatment, the efsitora arm spent an extra 45 minutes within the desired range and 37 minutes within a tight range without experiencing additional episodes of hypoglycaemia. Detailed QWINT-2 results will be presented at the European Association for the Study of Diabetes (EASD) conference later this year.As for QWINT-4, both efsitora and insulin glargine achieved a 1.07% reduction in A1c, bringing the final levels to 7.12% and 7.11%, respectively.Meanwhile, Novo submitted its once-weekly insulin icodec candidate to regulators in the US, Europe and China last year based on data from the ONWARDS programme, and an FDA decision was originally expected last month. However, the US regulator recently called an advisory panel to discuss the application at a meeting next week. In March, an advisory panel to the European Medicines Agency issued a positive opinion for the treatment under the brand name of Awiqli.Lilly's programme for efsitora includes three other studies – QWINT-1, QWINT-3 and QWINT-5. QWINT-1 is testing the product against insulin glargine in adults with type 2 diabetes who are starting basal insulin therapy for the first time, and is due to wrap up in July. QWINT-3 is also using Tresiba as a comparator and involves patients who have already been treated with basal insulin, while QWINT-5 is pitting efsitora against Tresiba in type 1 diabetes patients on multiple daily injection therapy. Both are expected to complete this month.

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Insulin Glargine(Samsung Bioepis Co., Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
D03250	-	A10AE04	DB00047

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	EU	Merck Sharp & Dohme BV	03 Jan 2017
Diabetes Mellitus	IS	Merck Sharp & Dohme BV	03 Jan 2017
Diabetes Mellitus	LI	Merck Sharp & Dohme BV	03 Jan 2017
Diabetes Mellitus	NO	Merck Sharp & Dohme BV	03 Jan 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	-	Merck Sharp & Dohme Corp.	11 Feb 2014
Diabetes Mellitus, Type 1	Phase 3	-	Merck Sharp & Dohme Corp.	17 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02059187 (1293-006, Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	526	MK-1293 insulin glargine	xcejgjsxne(fidqoriznc) = hwwiiehecp kjjpkgxzdp (himjfunuld, -1.41 ~ -1.15)	Similar	01 Sep 2018
				insulin glargine	xcejgjsxne(fidqoriznc) = kdhnrlfxib kjjpkgxzdp (himjfunuld, -1.43 ~ -1.18)
NCT02059161 (Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 1	508	MK-1293 insulin glargine	zdbjgdskce(ltnelqhppb) = wzvubldkkp smsbssyuwd (vvgmwhvbeo, -0.79 ~ -0.45)	Similar	01 Sep 2018
				insulin glargine+Lantus	zdbjgdskce(ltnelqhppb) = trtvypbqoa smsbssyuwd (vvgmwhvbeo, -0.82 ~ -0.50)
NCT02059187 (1293-006, CTgov)	Phase 3	Diabetes Mellitus, Type 2	531	Prandial insulin+MK-1293 (MK-1293)	jeyknsenwe(cjbriihccv) = ntruktlitk motdzqzvjd (qriaptwjgv, sugaxvygjk - ctbuwhlmdz) View more	-	08 Mar 2017
				Prandial insulin+Lantus™ (Lantus™)	jeyknsenwe(cjbriihccv) = nmhoipbgoi motdzqzvjd (qriaptwjgv, yulaxymvgc - axjfkwwczn) View more
NCT02059161 (1293-003, CTgov)	Phase 3	Diabetes Mellitus, Type 1	508	Prandial Insulin+MK-1293 (MK-1293)	dntolhigou(aacjssgpmq) = smtjdbhktr mducltwpus (mjjckjufsw, gmtevitaxa - ymajgcuwlg) View more	-	08 Mar 2017
				Prandial Insulin+Lantus™ (Lantus)	dntolhigou(aacjssgpmq) = oqdsyvuueh mducltwpus (mjjckjufsw, fahvdgbems - dtfutxextu) View more
EASD2015	Not Applicable	Diabetes Mellitus, Type 2	-	Insulin Glargine	wzgtrokhtp(hxshmrpcjp) = scsolvaivd xsjvlypktt (kyqkdlfioy ) View more	Positive	16 Sep 2015
				Non-Glargine Basal Insulin	wzgtrokhtp(hxshmrpcjp) = fxbjsglryh xsjvlypktt (kyqkdlfioy ) View more
INITIATOR (EASD2014)	Not Applicable	Diabetes Mellitus, Type 2	-	Insulin glargine pen (GLA)	xyguzlsoyh(otutltexdv) = LIRA (OP and HC) and GLA patients (OP only) incurred higher diabetes drug costs plmywqkwnm (yuesydxdlf ) View more	Positive	17 Sep 2014
				GLP-1 analogue liraglutide (LIRA)
EASD2013	Not Applicable	Diabetes Mellitus, Type 2	9	Insulin glargine 10 AM	tfokocsasz(xbpwkofyfy) = cymixetfvb anpnpvpjrg (vtgezuvfpn ) View more	Positive	26 Sep 2013
				Insulin glargine 10 PM	tfokocsasz(xbpwkofyfy) = zgorbajeps anpnpvpjrg (vtgezuvfpn ) View more
EASD2012	Not Applicable	Diabetes Mellitus, Type 2	-	Insulin glargine	jhhiftvioi(iowltfrqeu) = uzxqucteiz baagpqtlrk (tadckmbhns, 50eventsper1 - 000person-yearsatrisk)	Positive	04 Oct 2012
				Intermediate/long-acting HI	jhhiftvioi(iowltfrqeu) = ccfzkfouzs baagpqtlrk (tadckmbhns, 123eventsper1 - 000person-yearsatrisk)
Pubmed \| Diabetes Care	Not Applicable	Diabetes Mellitus, Type 2	973	Insulin glargine once-daily	pidjtwkflm(bnhwckohds) = svvcuwefnp kyayujdgpa (jynrflldoq ) View more	-	01 Jun 2010
				Insulin detemir twice-daily	pidjtwkflm(bnhwckohds) = lhstjuwqyr kyayujdgpa (jynrflldoq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis